Select Opportunities

• Phase 3-stage first-in-class oral visual cycle modulator for Stargardt disease

• Phase 2-stage first-in-class silk-derived protein-4 eyedrops for DED, superior limbic keratoconjunctivitis, and ocular inflammation

• Phase 1-stage first-in-class oral mitochondrial ATF4-ISR pathway modulator for r/r B-cell lymphomas, leukemias, and solid tumors

• Phase 1-stage first-in-class antibody for solid tumors

• Phase 1-stage first-in-class DNA polymerase β Inhibitor for cholangiocarcinoma and solid tumors

• Clinical-stage magnetically guided, biocompatible nanorobots for dental applications, and oncology tumor visualization & DDS

• IND-stage best-in-class oral PIM kinase inhibitors for RA, lupus, and orphan autoimmune diseases

• Preclinical-stage first-in-class cell-free targeted extracellular vesicle (EV) therapeutics for MASH and liver fibrosis, organ fibrosis, and inflammatory skin conditions

• Preclinical-stage best-in-class oral VAP-1 inhibitors for neuroinflammation, MASH, and DME

• Preclinical-stage best-in-class oral phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN)    

• Discovery/Preclinical-stage first-in-class small molecule mitochondrial dynamics regulators for obesity, metabolic disorders, healthspan, and neurodegenerative diseases